Synteract, Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Carlsbad CA United States (1986)
Status: Acquired by Syneos Health (2020)

Organization Overview

First Clinical Trial
2007
NCT00432562
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SynteractHCR | Synteract, Inc.

Active Ingredients

Drugs in Phase 4 Trials (2)

Key: Synteract, Inc. (1) Acquired (1)

bifidobacterium longum (1 trial)

sumatriptan (zecuity) (1 trial)

Drugs in Phase 3 Trials (11)

Key: Synteract, Inc. (9) Acquired (2)

Berdazimer (1 trial)

copper (cu-7) (1 trial)

dasiglucagon (Zegalogue) (1 trial)

dimethyl fumarate (tecfidera) (1 trial)

glucagon (1 trial)

nitric oxide (inomax) (2 trials)

pacritinib (Vonjo) (2 trials)

pxt3003 (1 trial)

rimabotulinumtoxinB (Myobloc) (2 trials)

sodium chloride (1 trial)

tretinoin (Retin-A) (1 trial)

Drugs in Phase 2 Trials (18)

Key: Synteract, Inc. (11) Acquired (7)

bc-dn-01 (1 trial)

butenafine (mentax) (1 trial)

c16g2 (1 trial)

Dapansutrile (1 trial)

depigold olea europea (1 trial)

entecavir (baraclude) (1 trial)

estetrol (NEXTSTELLIS) (1 trial)

inactivated influenza vaccine (1 trial)

levonorgestrel (1 trial)

mtg201 (1 trial)

nivolumab (opdivo) (1 trial)

phentermine (wyamine) (3 trials)

tenofovir (viread) (1 trial)

tetracycline (tetrex) (1 trial)

timothy grass pollen allergen extract (Grastek) (1 trial)

topiramate (topamax) (1 trial)

vancomycin (Vancocin) (1 trial)

Vonafexor (1 trial)

Drugs in Phase 1 Trials (8)

Key: Synteract, Inc. (6) Acquired (2)

cetuximab (erbitux) (1 trial)

fludarabine (fludara) (1 trial)

gefitinib (iressa) (1 trial)

ribavirin (virazole) (1 trial)

sd-101 (1 trial)

sweet vernal, orchard, perennial rye, timothy, and kentucky blue grass mixed pollens allergen extract (Oralair) (1 trial)

treosulfan (1 trial)

vinorelbine (navelbine) (1 trial)

Drugs in Other Trials (4)

Key: Synteract, Inc. (2) Acquired (2)

amaz-02 (1 trial)

cow milk (1 trial)

docosahexaenoic acid (1 trial)

lactobacillus casei (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 2)

Charcot-Marie-Tooth Disease (Phase 3)

Cystic Fibrosis (Phase 2)

Dental Caries (Phase 2)

Diabetes Mellitus (Phase 3)

Diabetes Mellitus, Type 1 (Phase 3)

Diabetes Mellitus, Type 2 (Phase 2)

Fibrosis (Phase 2)

Hepatitis (Phase 2)

Hepatitis A (Phase 1)

Hepatitis B (Phase 2)

Hepatitis B, Chronic (Phase 2)

Hepatitis C (Phase 1)

Hepatitis C, Chronic (Phase 1)

Hepatitis, Chronic (Phase 1)

Hereditary Sensory and Motor Neuropathy (Phase 3)

Hot Flashes (Phase 2)

Hypoglycemia (Phase 3)

Infections (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Mesothelioma (Phase 2)

Migraine Disorders (Phase 4)

Molluscum Contagiosum (Phase 3)

Nerve Compression Syndromes (Phase 3)

Ovarian Neoplasms (Phase 2)

Rhinitis (Phase 1)

Rhinitis, Allergic (Phase 1)

Rhinitis, Allergic, Seasonal (Phase 1)

Tooth Diseases (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 37
  • # of Trial APIs: 43